Clinical Trials
9 trialsNCT00064259 2021-02-17
A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer
National Cancer Institute (NCI)
Phase 1/2 Terminated
NCT00063934 2019-03-05
Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer
National Cancer Institute (NCI)
Phase 1/2 Terminated
NCT00003103 2013-07-03
Chemotherapy in Treating Patients With Solid Tumors
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT00062244 2013-06-04
Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00004870 2013-02-21
Olimersen and Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer
The University of Texas Health Science Center at San Antonio
Phase 1/2 Completed
NCT00005032 2013-02-11
Bcl-2 Antisense Oligodeoxynucleotide G3139 and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer
University of Chicago
Phase 1/2 Completed
NCT00086944 2013-01-24
Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00055822 2012-07-04
Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer
The University of Texas Health Science Center at San Antonio
Phase 1/2 Completed
NCT00021749 2009-11-13
Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia
Genta Incorporated
Phase 1/2 Completed